Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac 75 Efferdose could challenge Alka-Seltzer as leading effervescent stomach remedy.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 EFFERDOSE COULD CHALLENGE ALKA-SELTZER as the top effervescent OTC stomach remedy, following FDA's recent approval of Glaxo Wellcome's NDA for the effervescent tablet version of 75 mg ranitidine. Zantac 75 Efferdose is the first approved nonprescription effervescent H2 antagonist. FDA cleared the product for OTC marketing on Feb. 26, the day of the agency's original user fee goal ("The Tan Sheet" March 2, p. 1). Warner- Lambert, which markets Zantac 75, also will market the effervescent tablets.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088195

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel